### Cancer Surgery Standards PROGRAM

AMERICAN COLLEGE OF SURGEONS

# Best Practices for Compliance with CoC Standards 5.7 & 5.8

Thursday, June 3<sup>rd</sup> @ 8am CT



## Moderator



Matthew H.G. Katz

Professor

Department of Surgical Oncology

MD Anderson Cancer Center

Chair, Cancer Surgery Standards Program





## **Speakers**



Craig Messick, MD, FACS
MD Anderson Cancer Center
Houston, TX



**Tim Vreeland, MD, FACS**Brooke Army Medical Center
San Antonio, TX



Lexy Adams, MD, MPH Brooke Army Medical Center San Antonio, TX



Rashna Madan, MBBS
University of Kansas Medical Center
Kansas City, KS



Mariana Berho, MD Cleveland Clinic Weston, FL





## Cancer Surgery Standards PROGRAM AMERICAN COLLEGE OF SURGEONS

## Standard 5.7: Total Mesorectal Excision

Craig A. Messick, MD, FACS, FASCRS





| Standard | Disease Site | Procedure               | Documentation             |
|----------|--------------|-------------------------|---------------------------|
| 5.3      | Breast       | Sentinel node biopsy    | Operative report          |
| 5.4      | Breast       | Axillary dissection     | Operative report          |
| 5.5      | Melanoma     | Wide local excision     | Operative report          |
| 5.6      | Colon        | Colectomy (any)         | Operative report          |
| 5.7      | Rectum       | Mid/low resection (TME) | Pathology report<br>(CAP) |
| 5.8      | Lung         | Lung resection (any)    | Pathology report<br>(CAP) |






### **Operation**

Total mesorectal excision (TME) is performed for mid and low rectal tumors, resulting in **complete** or **near-complete** TME

Keep fascia propria of rectum intact, operate in plane between rectum and presacral fascia

- Ensures negative margins
- Protects neurovascular structures



## **Pathology Documentation**

Quality of TME documented in synoptic report:



### When?

2021: **Implementation** 

2022 site visits:

**70%** Compliance






## Why TME as a Standard?



## **TME Improves Oncologic Outcomes**




### Lower recurrence



### Kapiteijn E et al 2002. J Clin Oncol.

### **Prolonged overall survival**






## TME quality affects recurrence/survival



| Outcome                     | Complete<br>TME | Incomplete<br>TME | P-value |
|-----------------------------|-----------------|-------------------|---------|
| Overall recurrence (%)      | 14.9%           | 28.6%             | 0.03    |
| Local recurrence (%)        | 5.5%            | 11.4%             | 0.09    |
| Distant recurrence (%)      | 12.2%           | 19.2%             | 0.11    |
| 2-year overall survival (%) | 90.5%           | 76.9%             | <0.05   |



Nagtegaal et al 2002. J Clin Oncol





## **Documentation is Key!**



## **Scoring of TME Quality**



- TME quality scored by pathologist on CAP standardized synoptic report
- Score based on worst area of specimen, not the specimen as a whole

### Complete

- Intact bulky mesorectum w/ smooth surface, minor irregularities
- No surface defects >5mm
- No coning towards distal specimen

### **Near-complete**

- Moderate bulk to mesorectum
- Irregular mesorectal surface, + defects >5mm
- No visible muscularis propria except at insertion of levator muscles


### Incomplete


- Little bulk to mesorectum
- Defects down to muscularis propria
- Circumferential margin w/ irregular borders

### Complete, near complete, and incomplete TME










Near Complete Moderate quality

 Moderate bulk of mesorectum but some irregularity, moderate coning distally may be present.



Incomplete Poor quality

 Irregular mesorectum with defects more than 1 cm<sup>2</sup> or incision down to the muscularis propria, little bulk of mesorectum, little clearance anteriorly.

Photo courtesy of Dr. Patricia Sylla and Dr. Mariana Berho



## **CAP Synoptic Pathology Reporting**



### **Summary of Changes**

Version 4.1.0.0

The following data elements were modified:

Resection and biopsy case summaries separated into discrete cancer protocols

Histologic Type (WHO 2019)

Macroscopic Evaluation of Mesorectum (required for rectal cancers)

Modified Margins section

### **CAP Approved**

Gastrointestinal • Colon and Rectum• Resection • 4.1.0.0

Macroscopic Evaluation of Mesorectum (required for rectal cancers) (Note C)

Complete

Near complete
Incomplete
Cannot be determined

College of American Pathologists synoptic report templates available at:

https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates






## **Timeline**



## Timeline to achieve compliance








## Strategies to Optimize Compliance




## How can programs optimize compliance? \*\*Commission on Cancer\*\*









Perform TME and document indication (low-mid rectal tumor) clearly in operative notes

Ensure institution is utilizing standardized CAP reports for all rectal cancer procedures

**Encourage communication** amongst surgeons, pathologists, & registrars






### **Operation**

Total mesorectal excision (TME) is performed for mid and low rectal tumors, resulting in **complete** or **near-complete** TME


Keep fascia propria of rectum intact, operate in plane between rectum and presacral fascia

- Ensures negative margins
- Protects neurovascular structures



## **Pathology Documentation**

Quality of TME documented in synoptic report:



### When?

2021: **Implementation** 

2022 site visits:

**70%** Compliance



## Cancer Surgery Standards PROGRAM AMERICAN COLLEGE OF SURGEONS

## Standard 5.8: Pulmonary Resection

Timothy Vreeland, MD, FACS





| Standard | Disease Site | Procedure               | Documentation          |
|----------|--------------|-------------------------|------------------------|
| 5.3      | Breast       | Sentinel node biopsy    | Operative report       |
| 5.4      | Breast       | Axillary dissection     | Operative report       |
| 5.5      | Melanoma     | Wide local excision     | Operative report       |
| 5.6      | Colon        | Colectomy (any)         | Operative report       |
| 5.7      | Rectum       | Mid/low resection (TME) | Pathology report (CAP) |
| 5.8      | Lung         | Lung resection (any)    | Pathology report (CAP) |



### **Standard 5.8: Pulmonary Resection**



### **Operation**

## For any primary pulmonary resection performed with curative intent

(including non-anatomic parenchymal-sparing resections)

#### Resect nodal stations from:




Mediastinum (Stations 2-9) ≥3 distinct stations

Hilum (Stations 10-14) ≥1 station

### **Pathology Documentation**

### Synoptic report documents lymph nodes from:



with names and/or numbers of stations

When?

2021: **Implementation** 

2022 site visits:

**70%** Compliance

Adapted from Chest, Vol. 111, Mountain CF, Dresler CM, Regional lymph node classification for lung cancer staging, Pp. 1718-1723, Copyright (1997), with permission from Elsevier.











# Standard 5.8: Pulmonary Resection Operation





## For any primary pulmonary resection performed with curative intent

(including non-anatomic parenchymal-sparing resections)

### Resect nodal stations from:



Mediastinum (Stations 2-9) ≥3 distinct stations

**Hilum** (Stations 10-14) ≥1 station




### **Examining Mediastinal Lymph Nodes Improves Survival**



# Following NCCN quality resection guidelines improves survival

## NCCN Guidelines:

- 1. Anatomic resection
- 2. Negative margins
- 3. Examination of hilar/intrapulmonary LNs
- 4. Examination of ≥3 mediastinal LNs






### **Examining Mediastinal Lymph Nodes Improves Survival**



Nonexamination of MLNs decreases survival





### **Lymph Node Stations**



### **Superior Mediastinal Nodes**

- 1 Highest mediastinal
- 2 Upper paratracheal
- 3 Pre-vascular and retrotracheal
- 4 Lower paratracheal (including azygos nodes)

#### **Aortic Nodes**


- 5 Subaortic (A-P window)
- 6 Para-aortic (ascending aorta or phrenic)


#### Inferior Mediastinal Nodes

- 7 Subcarinal
- 8 Paraesophageal (below carina)
- 9 Pulmonary ligament

### N<sub>1</sub> Nodes


- 10 Hilar
- 11 Interlobar
- 12 Lobar
- 13 Segmental
- 14 Subsegmental
















# Standard 5.8: Pulmonary Resection Documentation



### **CoC Compliance Measures: Standard 5.8**



Nodal stations examined by the pathologist must be documented in any curative intent pulmonary resection in pathology reports in synoptic format

Nodal stations should be named and/or numbered, and this must be documented in the pathology report.



## Example of a CAP Lung Resection Synoptic Report



| CAP Approved Th  | orax • Lung • Resection • 4.1.0.1 |
|--|-----------------------------------|
| Surgical Pathology Cancer Case Summary   |                                   |
| Protocol posting date: February 2020   |                                   |
| LUNG: Resection  |                                   |
| Select a single response unless otherwise indicated.   |                                   |
| Synchronous Tumors (required if morphologically distinct unrelated multipersent#  Specify total number of primary tumors identified:  Specimen ID(s):  Cannot be determined  * Morphologically distinct tumors that are considered to represent separate primary lung synoptic reports  Procedure (select all that apply)  Wedge resection  Segmentectomy Lobectomy Completion lobectomy Sleeve lobectomy Bilobectomy Pneumonectomy Major airway resection (specify): Other (specify): Not specified  (apd Other Sections) | Number of Lymph Nodes Involved:   |
| Umph Node Examination (required only if lymph nodes present in the s   | specimen)                         |
| Number of Lymph Nodes Involved: Number cannot be determined (explain): Specify nodal station(s) involved (applieable only if node(s) invo  Number of Lymph Nodes Examined: Number cannot be determined (explain): Specify nodal station(s) examined:   |                                   |
| + Extranodal Extension (Note J) + Not identified + Present + Cannot be determined  |                                   |
| Treatment Effect (Note I)  No known presurgical therapy  |                                   |



Greater than 10% residual viable tumor Less than or equal to 10% residual viable tumor

Cannot be determined




# Standard 5.8: Pulmonary Resection Timeline



### **Standards 5.7 and 5.8 Requirements**





### **Standard 5.8: Pulmonary Resection**



### **Operation**

## For any primary pulmonary resection performed with curative intent

(including non-anatomic parenchymal-sparing resections)

#### Resect nodal stations from:




Mediastinum (Stations 2-9) ≥3 distinct stations

Hilum (Stations 10-14) ≥1 station

### **Pathology Documentation**

### Synoptic report documents lymph nodes from:



with names and/or numbers of stations

When?

2021: **Implementation** 

2022 site visits:

**70%** Compliance

Adapted from Chest, Vol. 111, Mountain CF, Dresler CM, Regional lymph node classification for lung cancer staging, Pp. 1718-1723, Copyright (1997), with permission from Elsevier.












# **Standard 5.8: Pulmonary Resection Strategies to Optimize Compliance**



### **How Can Programs Optimize Compliance?**





Label nodal stations
clearly and separately
during performance of
pulmonary resection


Ensure institution is utilizing standardized CAP reports for all lung cancer procedures

**Encourage**communication
amongst surgeons,
pathologists, & registrars



### **Lymph Node Stations**



































Station 11R






















Station 7



Station 9R



**Station 11R** 



Four separate specimens sent to pathology, clearly labeled.





## Pre-labeled Specimen Collection Kits & Checklists Improve Communication




Overall performance of mediastinal lymph node examination

Median number of MLN examined:

1














Osarogiagbon et al, 2012 Osarogiagbon et al, 2015





## Standardized Collection Kits Improve Compliance With Pulmonary Nodal Staging






Courtesy of Dr. Osarogiagbon



#### **How Can Programs Optimize Compliance?**





We encourage every institution to determine their own pathway to ensure the following:

- Adequate nodal sampling during surgery
- Proper pathologic evaluation
- Correct documentation of which nodal basins were resected and examined
- Correct data capture by registrars.



#### **How Can Programs Optimize Compliance?**





Label nodal stations clearly and separately during performance of pulmonary resection

Ensure institution is utilizing standardized CAP reports for all lung cancer procedures

Encourage
communication
amongst surgeons,
pathologists, & registrars



#### Cancer Surgery Standards PROGRAM

AMERICAN COLLEGE OF SURGEONS

## Case Study

Lexy Adams, MD, MPH



#### Single Site Review: Determining a Baseline



#### **Objectives:**

- To establish our institution's current adherence to Standards 5.7 and 5.8
- To identify deficits and to develop a site-specific plan to address them

#### **Methods:**

- Cases identified through surgical scheduling system
  - Another option: cancer registrar
- All operative and pathology reports reviewed for:
  - Mid to low rectal adenocarcinoma
  - Curative lung cancer resections
- Review team residents, with staff surgeon supervision



#### Single Site Review: Determining a Baseline



#### **Chart Review:** Investigate adherence to each contributing element

| Standard 5.7                            | Standard 5.8                    |
|---|---------------------------------|
| Standard                                | applies?                        |
| Appropriate surgical technique          | e detailed in operative report? |
| Complete or near complete TME performed | 3 MLN + 1 HLN resected          |
| Synoptic patholo                        | ogy report used?                |
| TME quality reported?                   | Lymph node stations reported?   |
| Meets standar                           | d completely?                   |



#### **Single Site Review: Baseline Results**



| Standard Elements               | Standard 5.7               | Standard 5.8   |
|---------------------------------|----------------------------|--|
| Standard applies?               | N = 12                     | N = 48   |
| Appropriate surgical technique? | 12 / 12                    | 18 / 48<br>(30/48 inadequate MLNS,<br>2/48 no HLN sampled) |
| Synoptic pathology report used? | 10 / 12                    | 46 / 48  |
| Pathology report includes:      | TME quality: <b>8 / 12</b> | Lymph node stations: 47 / 48                               |
| Meets standard completely?      | 6 / 12                     | 17 / 48  |

Overall Compliance: 50% 35%



#### Single Site Review: Identifying the Deficits



#### **Areas to Improve:**

#### **Standard 5.7 (Rectal)**

- Surgeon → Specify low/mid/high rectal tumors (3/12)
   Performance of TME stated in operative report (8/12)
- Pathology → Use of synoptic report to report TME quality (6/12)

#### **Standard 5.8 (Lung)**

Surgeon → Routinely take 3 MLN + 1 HLN,
 regardless of pre-operative EBUS

18/48 with adequate MLNS (0/6 with pre-op EBUS)
46/48 included HLN

If nodes are inaccessible, explicitly document so

• Pathology → Use of synoptic report with individual stations listed (47/48)



#### Single Site Review: Addressing the Deficits



#### **Interventions**:

- Discussion with Cancer Committee
  - Educational materials and video shared
  - Review of surgeon & pathology expectations
  - Chart review results reviewed, detailing areas requiring improvement





- Department leadership discussion & review of standards
  - Granular review of data helped clarify:
    - Definitions of MLN stations
    - Required 3 MLN + 1 HLN sampling despite pre-operative EBUS
    - Need for improved documentation for difficult dissections and inaccessible nodes



#### Single Site Review: Addressing the Deficits



#### **Outcomes for first half of 2021:**

#### **Overall Compliance:**

Standard 5.7 (Rectal)

**50%** 



100%

4/4 cases

Standard 5.8 (Lung)

**35%** 



100%

3/3 cases



#### **Beginning Your Site Review**



#### 1. Identify applicable cases

Use cancer registry or surgical schedule

#### 2. List all contributing elements required to meet standard

 Ex: surgical technique components, surgical documentation, specimen labeling, synoptic pathology report, report elements needed

#### 3. Simplify the chart review

Operative & pathology reports only – trainees can help!

#### 4. Identify & address the deficits

- Identify appropriate stakeholders, discuss within departments, share previously published videos & education materials, develop specimen labeling checklist, etc.
- Re-evaluate your progress!



#### Cancer Surgery Standards PROGRAM AMERICAN COLLEGE OF SURGEONS

# Standard 5.7: Total Mesorectal Excision

Pathological examination

Mariana Berho, MD



## Integrity of the Mesorectum



#### The plane of surgery correlates with the integrity of the mesorectum

Mesorectal: Complete mesorectum

Intramesorectal: Near complete mesorectum

Muscularis propria: Incomplete mesorectum





#### **Complete Mesorectum**























## **Scoring of TME Quality**



- TME quality scored by pathologist on CAP standardized synoptic report
- Score based on worst area of specimen, not the specimen as a whole

#### Complete

- Intact bulky mesorectum w/ smooth surface, minor irregularities
- No surface defects >5mm
- No coning towards distal specimen

#### **Near-complete**

- Moderate bulk to mesorectum
- Irregular mesorectal surface, + defects >5mm
- No visible muscularis propria except at insertion of levator muscles

#### Incomplete

- Little bulk to mesorectum
- Defects down to muscularis propria
- Circumferential margin w/ irregular borders



#### Protocol for the Examination of Resection Specimens From Patients With Primary Carcinoma of the Colon and Rectum

Version: Colon and Rectum Resection 4.1.0.0 Protocol Posting Date: February 2020

CAP Laboratory Accreditation Program Protocol Required Use Date: November 2020

Includes pTNM requirements from the 8th Edition, AJCC Staging Manual

https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates





#### **Summary of Changes**

Version 4.1.0.0

The following data elements were modified:

Resection and biopsy case summaries separated into discrete cancer protocols

Histologic Type (WHO 2019)

Macroscopic Evaluation of Mesorectum (required for rectal cancers)

Modified Margins section



#### CAP Cancer Protocol for Colon and Rectal Cancer Specimens



| CAP Approved                  | Gastrointestinal • Colon and Rectum• Resection • 4.1.0.0 |
|-------------------------------|--|
| Macroscopic Evaluati Complete | on of Mesorectum (required for rectal cancers) (Note C)  |
| Near complete                 |  |
| Cannot be determine           | ned  |






### Standard 5.7: Total Mesorectal Excision

## **Timeline**



### Timeline to achieve compliance





# Cancer Surgery Standards PROGRAM AMERICAN COLLEGE OF SURGEONS

# Standard 5.8: Pulmonary Resection

Pathologic Evaluation

Rashna Madan, MBBS



#### Surgeon

Specifically designated mediastinal/N2 and hilar/N1 nodal stations in separate specimen containers

Report in synoptic format

Registrar

Pathologist

N1 nodal stations dissected from main resection specimen





# College of American Pathologists (CAP) synoptic format for Pathology Reports

CoC Standard 5.1:

 90% of eligible cancer reports - synoptic reporting format -CAP cancer protocols...





## Protocol for the Examination of Resection Specimens From Patients With Primary Non-Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung

Version: Lung 4.1.0.1 Protocol Posting Date: February 2020

CAP Laboratory Accreditation Program Protocol Required Use Date: November 2020

Includes pTNM requirements from the 8th Edition, AJCC Staging Manual

https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates





## Lymph Node reporting - CAP synoptic format

- Conditional data element:
  - If lymph nodes are present, required to report:
    - Number
    - Specify stations

| Number of Lymph Nodes Involved:                           |                 |
|---|-----------------|
| Number cannot be determined (explain):                    |                 |
| Specify nodal station(s) involved (applicable only if nod | e(s) involved): |
|   |                 |
| Number of Lymph Nodes Examined:                           |                 |
| Number cannot be determined (explain):                    |                 |
| Number cannot be determined (explain):                    |                 |





# N1 nodes received as part of Main Resection specimen

- Nodes dissected out by the Pathology team
  - Peribronchial or intraparenchymal in location
- Count towards the Standard 5.8 requirement

Surgeons should perform hilar nodal dissection





## Fat only specimen

- Fat pad submitted from a station but no nodes identified on pathologic evaluation.
- Does not meet the requirement for Standard 5.8





## Nodes from Mediastinoscopy (prior)

- Nodes from mediastinoscopy can be utilized to meet requirements of Standard 5.8 if:
  - Documented in the same pathology report as the curative resection

 However endobronchial ultrasound (EBUS) needle biopsies of lymph nodes do not count towards Standard 5.8



## Pathologic nodal staging

- Standard 5.8 is a quality metric
- pN staging can be performed provided lymph nodes can be assessed even if the criteria for Standard 5.8 are not met:
  - Failure to meet the criteria does not imply pNX









